Find what you were looking for? Share your thoughts with a short survey

€26.8 million to fund diabetes research

A partnership comprising King’s College London and 22 academic, industry and third sector partners across Europe and the USA has been awarded €26.8 million to fund diabetes research.

hospital labDiabetes is a global pandemic, currently affecting around 60 million people in Europe. Patients with the disease are often unable to regulate their blood sugar so it can become dangerously high (hyperglycaemia) or dangerously low (hypoglycaemia). If left untreated, blood sugar levels can fall below the threshold for maintaining brain function leading to cognitive decline, cardiovascular complications and even death.

Much about hypoglycaemia remains unknown so the Innovative Medicines Initiative, an EU public-private partnership that funds health research and innovation, has awarded €26.8 million to 23 academic, industry and third sector partners across Europe and the USA. The aim of the project Hypo-RESOLVE (Hypoglycaemia – Redefining SOLutions for better liVEs) is to provide researchers and clinicians the tools to address the many unanswered questions.

The team at King’s College London will be led by Professor Stephanie Amiel, Head of Diabetes and Nutritional Sciences Division and Dr Pratik Choudhary, Consultant in Diabetes at King’s College Hospital NHS Foundation Trust and Senior Lecturer at King’s College London. They will examine the collective data from more than 100 clinical trials over the next four years. They hope to understand the full effect of hypoglycaemia and identify key risk factors and predictors in different populations. Dr Choudhary will also lead a multinational clinical study to reveal the extent and impact of ‘asymptomatic hypoglycaemia’, a milder form which, although often not recorded, is thought to be significantly detrimental to long-term health.

The project aims to create an international clinical database, conduct research to better understand the mechanisms and impact of hypoglycaemia and finally evaluate the financial cost to Europe and the countries involved. Key to this work will be the voices of people living with the disease. The Hypo-RESOLVE team plan substantial public and patient consultation to ensure that patients’ insights are considered and to strengthen public awareness of hypoglycaemia and diabetes generally.

The King’s Health Partners Diabetes, Endocrinology, Nutrition, Obesity, Vision and Related Services Clinical Academic Group (CAG) comprises the largest centre for metabolic disease in Europe. We are bringing together our partnership's clinical, research and educational expertise in diabetes medicine to develop a world-class Diabetes, Obesity and Endocrinology Institute

Read more on the King’s College London website.